Bellus Health Inc.
Clinical trials sponsored by Bellus Health Inc., explained in plain language.
Biopharma focused on chronic cough treatments, acquired by GSK.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New pill aims to silence chronic cough that Won't quit
Symptom relief CompletedThis study tests an experimental drug called BLU-5937 (camlipixant) in adults with refractory chronic cough, including unexplained chronic cough, that has lasted at least a year. Participants take the drug or a placebo daily for 52 weeks to see if it reduces coughing frequency an…
Phase 3 • Sponsor: Bellus Health Inc. - a GSK company • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Liver function may change how cough drug works
Knowledge-focused CompletedThis study looked at how camlipixant, an experimental drug for chronic cough, behaves in people with liver problems compared to healthy volunteers. 32 adults aged 18-75 took part to see if liver impairment changes drug levels or safety. The goal is to help doctors decide the righ…
Phase 1 • Sponsor: Bellus Health Inc. - a GSK company • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC